Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399658 · ClinicalTrials.gov registry record · Phase 2
Image-Guided Gynecologic Brachytherapy
A Phase 2 study of Cervical Cancer and Uterine Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT01399658: Completed Phase 2 study of Cervical Cancer and Uterine Cancer, sponsored by Dana-Farber Cancer Institute.
NCT01399658 is a Phase 2 study of Cervical Cancer and Uterine Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 93 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01399658, a Phase 2 study of Cervical Cancer and Uterine Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is practical and beneficial when compared to the standard CT-guided brachytherapy placement. The investigators are hoping that this MRI procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.
Primary Outcome
Doses given to the tumor, rectum, and sigmoid obtained after AMIGO-guided placement.
Conditions Studied
Interventions
- PROCEDURE Image-guided brachytherapy
- DRUG 3'-Deoxy-3'-18f-Fluorothymidine
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
What the finished NCT01399658 record still lists
NCT01399658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Image-guided brachytherapy is the first listed.
NCT01399658 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01399658 about?
NCT01399658 is a clinical study titled "Image-Guided Gynecologic Brachytherapy". Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the...
What is the current status of trial NCT01399658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2011-09. Estimated completion is 2016-06.
What conditions does trial NCT01399658 study?
This clinical trial studies the following conditions: Cervical Cancer, Uterine Cancer, Vaginal Cancer, Carcinoma of the Vulva.
What interventions are being tested in trial NCT01399658?
The interventions under investigation include: Image-guided brachytherapy (PROCEDURE), 3'-Deoxy-3'-18f-Fluorothymidine (DRUG).
Who is sponsoring clinical trial NCT01399658?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01399658 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01399658's enrollment target sits among peer trials
93 77th of 144 higher than 68 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia